查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1554406

2024-2032 年日本生物製品市场报告（按来源、产品、疾病、製造和地区）

Japan Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 121 Pages | 商品交期: 5-7个工作天内

价格
简介目录

预计 2024 年至 2032 年日本生物製品市场规模的成长率 (CAGR) 为 6.10%。对精准医疗方法的需求不断增长，对罕见疾病治疗的日益关注，以及癌症、类风湿关节炎、多发性硬化症和慢性发炎等慢性和复杂疾病盛行率的上升，是推动市场发展的一些关键因素。

生物製剂包括多种药物，包括单株抗体、疫苗、基因疗法和细胞疗法。它们源自活生物体或其成分，例如细胞、蛋白质、基因或组织。它们是透过生物技术方法生产的，与透过化学过程合成的传统化学药物不同。它们与体内的特定标靶相互作用以达到治疗效果。它们以其高特异性和有效性而闻名，与传统药物相比，通常副作用更少。它们刺激免疫系统产生免疫反应，而不会引起疾病本身，有助于保护个体免受各种病毒和细菌的侵害。它们可以根据患者疾病的特定遗传或分子特征进行定制，从而实现个人化治疗方法。与传统化学药物相比，它们可以促进组织再生和伤口癒合，并且副作用更少。它们透过增强身体针对癌细胞的免疫反应来帮助治疗某些类型的癌症。他们协助解决影响少数族群的罕见疾病和孤儿疾病。它们用于治疗、预防或控制各种医疗状况和疾病。随着它们透过有效管理症状和减缓疾病进展来改善患者的生活质量，日本对生物製剂的需求正在上升。

日本生物製剂市场趋势：

目前，癌症、类风湿性关节炎、多发性硬化症和慢性发炎等慢性和复杂疾病在个人中的盛行率不断增加，这是促进日本市场成长的主要因素之一。此外，生物製剂的使用不断增加，因为它们降低了住院频率和严重程度，正在加强该国市场的成长。除此之外，对精准医疗方法不断增长的需求也带来了积极的市场前景。此外，患者对生物製剂益处的认识不断提高，例如副作用更少、住院时间缩短和治疗效果持久，这为日本的行业投资者提供了利润丰厚的成长机会。与此一致的是，对治疗癌症的免疫疗法和单株抗体的需求不断增长，正在对市场产生积极影响。此外，生物生产方法的创新有利于生物製剂的成本效益和高效生产，从而促进了市场的成长。除此之外，该国生物製剂临床试验数量的增加正在推动市场成长。此外，大众对治疗罕见疾病的日益关注正在推动市场成长。生物技术和基因组学的技术进步促进了新型生物製剂的发现和开发，这也支持了日本市场的成长。

日本生物製品市场区隔：

IMARC Group提供了每个细分市场的主要趋势的分析，以及 2024-2032 年国家层级的预测。我们的报告根据来源、产品、疾病和製造对市场进行了分类。

来源见解：

  • 微生物
  • 哺乳动物
  • 其他的

该报告根据来源提供了详细的市场细分和分析。这包括微生物、哺乳动物等。

产品见解：

  • 单株抗体
  • 疫苗
  • 重组蛋白
  • 反义、RNAi 和分子治疗
  • 其他的

报告还提供了基于该产品的详细市场细分和分析。这包括单株抗体、疫苗、重组蛋白、反义、RNAi 和分子疗法等。

疾病见解：

  • 肿瘤学
  • 免疫系统疾病
  • 心血管疾病
  • 血液系统疾病
  • 其他的

该报告根据疾病提供了详细的市场细分和分析。这包括肿瘤学、免疫学疾病、心血管疾病、血液学疾病等。

製造洞察：

  • 外包
  • 内部

报告还提供了基于製造的详细市场细分和分析。这包括外包和内部。

区域见解：

  • 关东地区
  • 关西/近畿地区
  • 中部/中部地区
  • 九州·冲绳地区
  • 东北部地区
  • 中国地区
  • 北海道地区
  • 四国地区

该报告还对所有主要区域市场进行了全面分析，包括关东地区、关西/近畿地区、中部/中部地区、九州冲绳地区、东北地区、中国地区、北海道地区和四国地区。

竞争格局：

市场研究报告也对竞争格局进行了全面分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本生物製品市场迄今表现如何，未来几年又将如何表现？
  • COVID-19 对日本生物製品市场有何影响？
  • 日本生物製剂市场依来源划分是怎样的？
  • 日本生物製剂市场依产品划分是怎样的？
  • 日本生物製品市场因疾病而分裂的原因是什么？
  • 日本生物製品市场在製造业基础上的分化是什么？
  • 日本生物製品市场价值链的各个阶段是什么？
  • 日本生物製品的关键驱动因素和挑战是什么？
  • 日本生物製剂市场的结构如何？
  • 日本生物製剂市场的竞争程度如何？

本报告回答的关键问题：

  • 日本生物製品市场迄今表现如何，未来几年又将如何表现？
  • COVID-19 对日本生物製品市场有何影响？
  • 日本生物製剂市场依来源划分是怎样的？
  • 日本生物製剂市场依产品划分是怎样的？
  • 日本生物製品市场因疾病而分裂的原因是什么？
  • 日本生物製剂市场在製造业基础上的分化是什么？
  • 日本生物製品市场价值链的各个阶段是什么？
  • 日本生物製品的关键驱动因素和挑战是什么？
  • 日本生物製品市场的结构如何？
  • 日本生物製剂市场的竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：日本生物製剂市场 - 简介

  • 概述
  • 市场动态
  • 产业动态
  • 竞争情报

第 5 章：日本生物製剂市场格局

  • 历史与当前市场趋势（2018-2023）
  • 市场预测（2024-2032）

第 6 章：日本生物製剂市场 - 细分：依来源分类

  • 微生物
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 哺乳动物
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 7 章：日本生物製剂市场 - 细分：依产品分类

  • 单株抗体
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 疫苗
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 重组蛋白
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 反义、RNAi 和分子治疗
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 8 章：日本生物製剂市场 - 细分：依疾病分类

  • 肿瘤学
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 免疫系统疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 心血管疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 血液系统疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 9 章：日本生物製剂市场 - 细分：依製造业划分

  • 外包
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 内部
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 10 章：日本生物製剂市场 - 细分：按地区

  • 关东地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）
  • 关西/近畿地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）
  • 中部/中部地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）
  • 九州·冲绳地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）
  • 东北部地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）
  • 中国地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）
  • 北海道地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）
  • 四国地区
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔：依来源
    • 市场区隔：按产品
    • 市场区隔：依疾病分类
    • 市场区隔：依製造业
    • 关键参与者
    • 市场预测（2024-2032）

第 11 章：日本生物製剂市场 - 竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳制胜策略
  • 竞争仪表板
  • 公司评估象限

第 12 章：关键参与者简介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

此处未提供公司名称，因为这是目录范例。报告中提供了完整的清单。

第 13 章：日本生物製剂市场 - 产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 司机
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 14 章：附录

简介目录
Product Code: SR112024A19698

Japan biologics market size is projected to exhibit a growth rate (CAGR) of 6.10% during 2024-2032. The growing demand for precision medicine approaches, increasing focus on treating rare diseases, and rising prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, represent some of the key factors driving the market.

Biologics comprise a wide range of pharmaceuticals, including monoclonal antibodies, vaccines, gene therapies, and cell-based therapies. They are derived from living organisms or their components, such as cells, proteins, genes, or tissues. They are produced through biotechnological methods, unlike traditional chemical-based drugs that are synthesized through chemical processes. They interact with specific targets in the body to achieve therapeutic effects. They are known for their high specificity and efficacy, often resulting in fewer side effects compared to conventional drugs. They stimulate the immune system to produce an immune response without causing the disease itself, helping to protect individuals from various viruses and bacteria. They can be tailored to specific genetic or molecular characteristics of disease of patient, enabling personalized treatment approaches. They promote tissue regeneration and wound healing and have fewer side-effects as compared to traditional chemical drugs. They aid in treating certain types of cancer by enhancing the immune response of the body against cancer cells. They assist in addressing rare diseases and orphan diseases that affect a small population. They are used to treat, prevent, or manage various medical conditions and diseases. As they improve the quality of life for patients by effectively managing symptoms and slowing disease progression, the demand for biologics is rising in Japan.

Japan Biologics Market Trends:

At present, the increasing prevalence of chronic and complex diseases, such as cancer, rheumatoid arthritis, multiple sclerosis, and chronic inflammatory conditions, among individuals represents one of the major factors contributing to the market growth in Japan. Moreover, the rising usage of biologics, as they reduce the frequency and severity of hospitalizations, is strengthening the growth of the market in the country. Apart from this, the escalating demand for precision medicine approaches is offering a positive market outlook. Additionally, the increasing awareness among patients about the benefits of biologics, such as fewer side effects, reduced hospital stays, and long-lasting therapeutic effects, is providing lucrative growth opportunities to industry investors in Japan. In line with this, the growing demand for immunotherapies and monoclonal antibodies for treating cancer is influencing the market positively. In addition, innovations in bioproduction methods benefit in cost-effective and efficient production of biologics, which is bolstering the growth of the market. Besides this, the rising number of clinical trials for biologics in the country is propelling the market growth. Furthermore, the increasing focus on treating rare diseases among the masses is impelling the market growth. The technological advancement in biotechnology and genomics enhances the discovery and development of novel biologics, which is also supporting the market growth in Japan.

Japan Biologics Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2024-2032. Our report has categorized the market based on source, product, disease, and manufacturing.

Source Insights:

  • Microbial
  • Mammalian
  • Others

The report has provided a detailed breakup and analysis of the market based on the source. This includes microbial, mammalian, and others.

Product Insights:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi and Molecular Therapy
  • Others

A detailed breakup and analysis of the market based on the product have also been provided in the report. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others.

Disease Insights:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

The report has provided a detailed breakup and analysis of the market based on the disease. This includes oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others.

Manufacturing Insights:

  • Outsourced
  • In-House

A detailed breakup and analysis of the market based on the manufacturing have also been provided in the report. This includes outsourced and in-house.

Regional Insights:

  • Kanto Region
  • Kansai/Kinki Region
  • Central/ Chubu Region
  • Kyushu-Okinawa Region
  • Tohoku Region
  • Chugoku Region
  • Hokkaido Region
  • Shikoku Region

The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan biologics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan biologics market?
  • What is the breakup of the Japan biologics market on the basis of source?
  • What is the breakup of the Japan biologics market on the basis of product?
  • What is the breakup of the Japan biologics market on the basis of disease?
  • What is the breakup of the Japan biologics market on the basis of manufacturing?
  • What are the various stages in the value chain of the Japan biologics market?
  • What are the key driving factors and challenges in the Japan biologics?
  • What is the structure of the Japan biologics market and who are the key players?
  • What is the degree of competition in the Japan biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Biologics Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Biologics Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Biologics Market - Breakup by Source

  • 6.1 Microbial
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Forecast (2024-2032)
  • 6.2 Mammalian
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)
  • 6.3 Others
    • 6.3.1 Historical and Current Market Trends (2018-2023)
    • 6.3.2 Market Forecast (2024-2032)

7 Japan Biologics Market - Breakup by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Vaccines
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)
  • 7.3 Recombinant Proteins
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2018-2023)
    • 7.3.3 Market Forecast (2024-2032)
  • 7.4 Antisense, RNAi and Molecular Therapy
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2018-2023)
    • 7.4.3 Market Forecast (2024-2032)
  • 7.5 Others
    • 7.5.1 Historical and Current Market Trends (2018-2023)
    • 7.5.2 Market Forecast (2024-2032)

8 Japan Biologics Market - Breakup by Disease

  • 8.1 Oncology
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Immunological Disorders
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)
  • 8.3 Cardiovascular Disorders
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2018-2023)
    • 8.3.3 Market Forecast (2024-2032)
  • 8.4 Hematological Disorders
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2018-2023)
    • 8.4.3 Market Forecast (2024-2032)
  • 8.5 Others
    • 8.5.1 Historical and Current Market Trends (2018-2023)
    • 8.5.2 Market Forecast (2024-2032)

9 Japan Biologics Market - Breakup by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2018-2023)
    • 9.1.3 Market Forecast (2024-2032)
  • 9.2 In-House
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2018-2023)
    • 9.2.3 Market Forecast (2024-2032)

10 Japan Biologics Market - Breakup by Region

  • 10.1 Kanto Region
    • 10.1.1 Overview
    • 10.1.2 Historical and Current Market Trends (2018-2023)
    • 10.1.3 Market Breakup by Source
    • 10.1.4 Market Breakup by Product
    • 10.1.5 Market Breakup by Disease
    • 10.1.6 Market Breakup by Manufacturing
    • 10.1.7 Key Players
    • 10.1.8 Market Forecast (2024-2032)
  • 10.2 Kansai/Kinki Region
    • 10.2.1 Overview
    • 10.2.2 Historical and Current Market Trends (2018-2023)
    • 10.2.3 Market Breakup by Source
    • 10.2.4 Market Breakup by Product
    • 10.2.5 Market Breakup by Disease
    • 10.2.6 Market Breakup by Manufacturing
    • 10.2.7 Key Players
    • 10.2.8 Market Forecast (2024-2032)
  • 10.3 Central/ Chubu Region
    • 10.3.1 Overview
    • 10.3.2 Historical and Current Market Trends (2018-2023)
    • 10.3.3 Market Breakup by Source
    • 10.3.4 Market Breakup by Product
    • 10.3.5 Market Breakup by Disease
    • 10.3.6 Market Breakup by Manufacturing
    • 10.3.7 Key Players
    • 10.3.8 Market Forecast (2024-2032)
  • 10.4 Kyushu-Okinawa Region
    • 10.4.1 Overview
    • 10.4.2 Historical and Current Market Trends (2018-2023)
    • 10.4.3 Market Breakup by Source
    • 10.4.4 Market Breakup by Product
    • 10.4.5 Market Breakup by Disease
    • 10.4.6 Market Breakup by Manufacturing
    • 10.4.7 Key Players
    • 10.4.8 Market Forecast (2024-2032)
  • 10.5 Tohoku Region
    • 10.5.1 Overview
    • 10.5.2 Historical and Current Market Trends (2018-2023)
    • 10.5.3 Market Breakup by Source
    • 10.5.4 Market Breakup by Product
    • 10.5.5 Market Breakup by Disease
    • 10.5.6 Market Breakup by Manufacturing
    • 10.5.7 Key Players
    • 10.5.8 Market Forecast (2024-2032)
  • 10.6 Chugoku Region
    • 10.6.1 Overview
    • 10.6.2 Historical and Current Market Trends (2018-2023)
    • 10.6.3 Market Breakup by Source
    • 10.6.4 Market Breakup by Product
    • 10.6.5 Market Breakup by Disease
    • 10.6.6 Market Breakup by Manufacturing
    • 10.6.7 Key Players
    • 10.6.8 Market Forecast (2024-2032)
  • 10.7 Hokkaido Region
    • 10.7.1 Overview
    • 10.7.2 Historical and Current Market Trends (2018-2023)
    • 10.7.3 Market Breakup by Source
    • 10.7.4 Market Breakup by Product
    • 10.7.5 Market Breakup by Disease
    • 10.7.6 Market Breakup by Manufacturing
    • 10.7.7 Key Players
    • 10.7.8 Market Forecast (2024-2032)
  • 10.8 Shikoku Region
    • 10.8.1 Overview
    • 10.8.2 Historical and Current Market Trends (2018-2023)
    • 10.8.3 Market Breakup by Source
    • 10.8.4 Market Breakup by Product
    • 10.8.5 Market Breakup by Disease
    • 10.8.6 Market Breakup by Manufacturing
    • 10.8.7 Key Players
    • 10.8.8 Market Forecast (2024-2032)

11 Japan Biologics Market - Competitive Landscape

  • 11.1 Overview
  • 11.2 Market Structure
  • 11.3 Market Player Positioning
  • 11.4 Top Winning Strategies
  • 11.5 Competitive Dashboard
  • 11.6 Company Evaluation Quadrant

12 Profiles of Key Players

  • 12.1 Company A
    • 12.1.1 Business Overview
    • 12.1.2 Product Portfolio
    • 12.1.3 Business Strategies
    • 12.1.4 SWOT Analysis
    • 12.1.5 Major News and Events
  • 12.2 Company B
    • 12.2.1 Business Overview
    • 12.2.2 Product Portfolio
    • 12.2.3 Business Strategies
    • 12.2.4 SWOT Analysis
    • 12.2.5 Major News and Events
  • 12.3 Company C
    • 12.3.1 Business Overview
    • 12.3.2 Product Portfolio
    • 12.3.3 Business Strategies
    • 12.3.4 SWOT Analysis
    • 12.3.5 Major News and Events
  • 12.4 Company D
    • 12.4.1 Business Overview
    • 12.4.2 Product Portfolio
    • 12.4.3 Business Strategies
    • 12.4.4 SWOT Analysis
    • 12.4.5 Major News and Events
  • 12.5 Company E
    • 12.5.1 Business Overview
    • 12.5.2 Product Portfolio
    • 12.5.3 Business Strategies
    • 12.5.4 SWOT Analysis
    • 12.5.5 Major News and Events

Company names have not been provided here as this is a sample TOC. The complete list is provided in the report.

13 Japan Biologics Market - Industry Analysis

  • 13.1 Drivers, Restraints, and Opportunities
    • 13.1.1 Overview
    • 13.1.2 Drivers
    • 13.1.3 Restraints
    • 13.1.4 Opportunities
  • 13.2 Porters Five Forces Analysis
    • 13.2.1 Overview
    • 13.2.2 Bargaining Power of Buyers
    • 13.2.3 Bargaining Power of Suppliers
    • 13.2.4 Degree of Competition
    • 13.2.5 Threat of New Entrants
    • 13.2.6 Threat of Substitutes
  • 13.3 Value Chain Analysis

14 Appendix